At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 155 enrolled
Drug / intervention
LX1031 High Dose +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 2, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Multiple-Dose Study to Determine the Safety and Efficacy of Orally Administered LX1031 in Subjects With Non-Constipating Irritable Bowel Syndrome
In Brief
A Phase 2 clinical trial evaluating LX1031 High Dose, LX1031 Low Dose, and 1 other intervention for Irritable Bowel Syndrome. Completed, enrolled 155 participants across 36 sites.
Detailed Summary
The purpose of the study is to evaluate the safety, tolerability, and effectiveness of LX1031 versus a placebo control in subjects with non-constipating irritable bowel syndrome.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsIrritable Bowel Syndrome
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
Enrollment StartDec 2008
First PostedDec 2008
Primary CompletionJul 2009
Study CompletionAug 2010
TodayJul 2026
First PostedDec 22, 2008
Enrollment StartDec 1, 2008
Primary CompletionJul 1, 2009
Study CompletionAug 1, 2010
TodayJul 2, 2026
Enrollment to primary: 7 monthsPosted 17.5 years ago
Interventions
LX1031 High Dosedrug
A high dose of LX1031; daily oral intake for 28 days
LX1031 Low Dosedrug
A low dose of LX1031; daily oral intake for 28 days.
Placebodrug
Matching placebo dosing with daily oral intake